Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Meyers JL, Parasuraman S, Bell K, Graham JP, Candrilli SD. The high-cost, type 2 diabetes mellitus patient: an analysis of managed care administrative data. Arch Public Health. 2014 Feb 27;72(1):6.
Ruiz-Castell M, Carsin AE, Barbieri FL, Paco P, Gardon J, Sunyer J. Child patterns of growth delay and cognitive development in a Bolivian mining city. Am J Hum Biol. 2013 Jan;25(1):94-100. doi: 10.1002/ajhb.22346